Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYRS
Previous Symbol
CUSIPN/A
Phone617-744-1340
Debt
Debt-to-Equity RatioN/A
Current Ratio5.43
Quick Ratio5.43
Price-To-Earnings
Trailing P/E Ratio-3.50
Forward P/E Ratio-3.98
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.10 million
Price / Sales227.90
Cash FlowN/A
Price / CashN/A
Book Value$2.40 per share
Price / Book3.10
Profitability
EPS (Most Recent Fiscal Year)($2.13)
Net Income$-54,010,000.00
Net MarginsN/A
Return on Equity-63.80%
Return on Assets-51.94%
Miscellaneous
Employees56
Outstanding Shares33,650,000
Market Cap$274.62 million
OptionableOptionable
Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions
What is Syros Pharmaceuticals' stock symbol?
Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."
How were Syros Pharmaceuticals' earnings last quarter?
Syros Pharmaceuticals Inc (NASDAQ:SYRS) released its quarterly earnings results on Thursday, November, 1st. The company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.02. The company earned $0.41 million during the quarter, compared to analyst estimates of $0.72 million. View Syros Pharmaceuticals' Earnings History.
When is Syros Pharmaceuticals' next earnings date?
What price target have analysts set for SYRS?
7 Wall Street analysts have issued 1-year price targets for Syros Pharmaceuticals' stock. Their forecasts range from $10.00 to $33.00. On average, they expect Syros Pharmaceuticals' share price to reach $20.00 in the next year. This suggests a possible upside of 167.4% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals.
What is the consensus analysts' recommendation for Syros Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals.
What are Wall Street analysts saying about Syros Pharmaceuticals stock?
Here are some recent quotes from research analysts about Syros Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (11/6/2018)
- 2. Cann analysts commented, "Syros’ 3Q18 loss per share was $0.47, in line with our estimate. Operating expenses of $16.7 million were slightly higher than our estimated $16.3 million, but were offset by higher interest income and slightly higher number of shares outstanding. There were no other remarkable variances in the quarter. Syros has a number of data presentations approaching, which we believe are very important for the company." (11/1/2018)
- 3. HC Wainwright analysts commented, "Our price target of $10/share ($3.38 from tamibarotene + $2.35 from platform + $3.83 in cash) is based on a discounted cash flow analysis (2018-2027) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development-stage oncology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing." (8/8/2018)
Has Syros Pharmaceuticals been receiving favorable news coverage?
News stories about SYRS stock have trended very positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 3.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Syros Pharmaceuticals' key competitors?
Some companies that are related to Syros Pharmaceuticals include Zai Lab (ZLAB), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Alder Biopharmaceuticals (ALDR), Puma Biotechnology (PBYI), ImmunoGen (IMGN), Dicerna Pharmaceuticals (DRNA), Clovis Oncology (CLVS), Intra-Cellular Therapies (ITCI), Kiniksa Pharmaceuticals (KNSA), Akorn (AKRX), Deciphera Pharmaceuticals (DCPH) and Y-mAbs Therapeutics (YMAB).
Who are Syros Pharmaceuticals' key executives?
Syros Pharmaceuticals' management team includes the folowing people:
- Dr. Nancy A. Simonian, Pres, CEO & Director (Age 57)
- Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 64)
- Dr. David A. Roth, Chief Medical Officer (Age 55)
- Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 56)
- Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board
When did Syros Pharmaceuticals IPO?
(SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Syros Pharmaceuticals' major shareholders?
Syros Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), ARK Investment Management LLC (6.60%), Redmile Group LLC (4.92%), BlackRock Inc. (4.80%), JPMorgan Chase & Co. (1.10%) and JPMorgan Chase & Co. (1.10%). Company insiders that own Syros Pharmaceuticals stock include Colleen Elizabeth Desimone, Eric R Olson, Jeremy P Springhorn, Richard A Young and Srinivas Akkaraju. View Institutional Ownership Trends for Syros Pharmaceuticals.
Which institutional investors are selling Syros Pharmaceuticals stock?
SYRS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Point72 Asset Management L.P., Virtus ETF Advisers LLC, TIAA CREF Investment Management LLC, Los Angeles Capital Management & Equity Research Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Syros Pharmaceuticals.
Which institutional investors are buying Syros Pharmaceuticals stock?
SYRS stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, FMR LLC, Dimensional Fund Advisors LP, Wedge Capital Management L L P NC, GSA Capital Partners LLP, BlackRock Inc., Redmile Group LLC and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals.
How do I buy shares of Syros Pharmaceuticals?
Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syros Pharmaceuticals' stock price today?
One share of SYRS stock can currently be purchased for approximately $7.48.
How big of a company is Syros Pharmaceuticals?
Syros Pharmaceuticals has a market capitalization of $274.62 million and generates $1.10 million in revenue each year. The company earns $-54,010,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Syros Pharmaceuticals employs 56 workers across the globe.
What is Syros Pharmaceuticals' official website?
How can I contact Syros Pharmaceuticals?
Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]
MarketBeat Community Rating for Syros Pharmaceuticals (NASDAQ SYRS)
MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
